Conclusions: Patients with symptomatic AAA had worse long-term survival and similar aneurysm-related reinterventions compared with patients with asymptomatic AAA undergoing repair. Differences in longterm survival appear to be only partially explained by measured patient, aneurysm, and operative factors. Objectives: Over the past 15 years, as endovascular aortic aneurysm repair has become the principal mode of intact abdominal aortic aneurysm (AAA) repair, the frequency of open surgical repair (OSR) has decreased. There is little evidence in the literature about the effect of surgeon volume on procedure value. In the setting of decreased rates of OSR in patients with more complex anatomy, the hypothesis of this study is that high-volume surgeons will provide improved value by having lower rates of morbidity and mortality.
Objectives: Although endovascular aortic repair (EVAR) is the preferred treatment for abdominal aortic aneurysms (AAA), postoperative acute myocardial infarction (MI) and arrest remains a significant cause of morbidity and mortality. The Vascular Quality Initiative Cardiac Risk Index was developed to predict MI following elective vascular surgery including EVAR. We identify patient and hospital-level predictors of major adverse cardiac events (MACE) after EVAR in the largest national inpatient database. Hospital volume (No./year) 43.5 6 0.6 28.9 6 0.4 <.0001
Surgeon volume (No./year) 15.6 6 0.2 8.3 6 0.1 <.0001
3-year survival (%) 95.2 6 0.3 66.4 6 0.6 <.0001
30-day survival (%) 100.0 6 0.0 89.9 6 0.4 <.0001
Charge ($k) a 33.5 6 0.2 147.7 6 1.9 <.0001
30-day readmission (%) 0.6 6 0.1 3.5 6 0. (Table IV) : wound (7.25% vs 1.88%; P < .0001), infection (2.25% vs 0.24%; P < .0001), urinary (2.5% vs 1.14%; P ¼ .0109), pulmonary (10.75% vs 1.35%; P < .0001), gastrointestinal (1.25% vs 0.48%; P ¼ .0467), shock (2.25% vs 0.13%; P < .0001), intraoperative puncture (5% vs 0.7%; P < .0001), hemorrhage (5.5% vs 1.02%; P < .0001), and phlebitis (2.75% vs 0.55%; P < .0001). The average LOS was 9.54 days for patients with MACE compared to 2.53 days (P < .0001; Table V) . Patients who experienced MACE incurred $53,630 per hospitalization compared with $26,915 (P < .0001). MACE was associated with a higher rate of nonroutine discharge (63% vs 16.49%; P < .0001) and mortality (22.5% vs 0.42%; P < .0001).
Conclusions:
The top predictors for MACE are fluid and electrolyte disorders, malnutrition, Asian race, and CAD. Although less than 1% of patients undergoing EVAR experience major cardiac complications, it is associated with a $26,715 increase in cost and a 22.5% mortality rate.
Author Disclosures: R. Dayal: Nothing to disclose; G. GonzalezGuardiola: Nothing to disclose; A. Lee: Nothing to disclose; P. Vuong: Nothing to disclose. Objectives: Vascular surgeons are frequently consulted to evaluate hospitalized patients in the intensive care unit (ICU) with finger ischemia. We sought to characterize causes and outcomes of finger ischemia in ICU patients.
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Causes and Outcomes of Finger Ischemia in
Methods: All ICU patients who underwent evaluation for finger ischemia from 2008 to 2015 were reviewed. All were evaluated with finger plethysmography. Patient demographics, comorbidities, ICU care (ventilator status, arterial lines, use of vasoactive medications), finger amputations, and survival were recorded.
Results: We identified 97 patients (54 male, 43 female). Mean age was 57.3 6 16.8. Of these patients, 42 (43%) were in the surgical ICU and 55 (57%) in the medical ICU, 70 (72%) had abnormal results on finger plethysmographies, 67 (69%) unilateral and 30 (31%) bilateral, 36 (37%) had ischemia associated with an arterial line, 12 (13%) had concomitant toe ischemia, and 76 (78%) were on vasoactive medications at the time of diagnosis, with the most frequent being phenylephrine (55%), norepinephrine (47%), ephedrine (30%), epinephrine (26%), vasopressin (25%), dopamine (7%), dobutamine (6%).Treatment was with therapeutic anticoagulation in 46 (47%), aspirin in 50 (52%), and clopidogrel in 15 (16%). Other frequent associated conditions included mechanical ventilation at the time of diagnosis (37%), diabetes (33%), history of peripheral vascular disease (32%), dialysis dependence (31%), cancer (24%), and sepsis (20%). Only five patients (5%) ultimately required finger amputation. The 30-day, 1-year, and 2-year survival were 85%, 73%, and 65%. By Cox proportional hazards modelling, cancer (hazard ratio, 6.3; P ¼ .012) and dialysis (hazard ratio, 4.9; P ¼ .026) were independent predictors of mortality.
Conclusions: Finger ischemia in ICU patients has a variety of causes but is frequently associated with the presence of arterial lines and the use of vasoactive medications, of which phenylephrine and norepinephrine are the most frequent. Either anticoagulation or antiplatelet therapy is appropriate treatment. While progression to amputation is rare, patients with finger ischemia in the ICU have a high rate of mortality, particularly in the presence of cancer or dialysis.
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The Impact of Cannula-Related Limb Ischemia on ECMO Patient Survival Luis Suarez, Mark Iafrati. Tufts Medical Center, Waltham, Mass
Objectives: Multiple mechanical devices are available to support patients with cardiovascular collapse due to acute heart failure. When partial support methods, such as balloon pumps or Impella devices are inadequate, the last lifesaving effort is the use of venous-arterial (VA) extracorporeal membrane oxygen (ECMO) circuits to support these patients while organ systems recover or as a bridge to further surgical therapies. ECMO, however, uses large arterial and venous cannulae and is associated with a risk of device-related lower extremity ischemia. Use of an antegrade perfusion cannula inserted into the superficial femoral artery has been proposed as a method to mitigate this risk.
Methods: We retrospectively reviewed our prospectively gathered institutional database of adult patients requiring VA ECMO for the past 4 years (2013) (2014) (2015) (2016) and sought to describe the outcomes and the impact of limb ischemia and the use of an antegrade arterial limb perfusion cannula on mortality.
Results: There were 63 adult patients treated with VA ECMO for acute heart failure in 2013 to 2016, with an overall mortality of 51% (32 of 63). Limb ischemia was noted in 29% of patients. Mortality of patients with limb ischemia was 78% vs 43% for those without limb ischemia (RR, 1.83; 95% confidence interval, 1.2-2.8; P ¼ .005). During the first 2 years, antegrade cannulas were not routinely used (3 of 22 [14%]) whereas in the latter 2 years, antegrade cannulas were recommended (26 of 41 [63%]). Antegrade cannula insertion was performed prophylactically in 23 of 26 (88%), with the remaining three superficial femoral artery cannulas inserted after limb ischemia was noted. The mortality of patients that received an antegrade cannula at the time of ECMO initiation was 45% vs 56% for those who did not (RR, 0.8; 95% confidence interval, 0.48-1.32; P ¼ .38).
Conclusions: Patients on ECMO who develop limb ischemia have increased mortality compared to those without acute limb ischemia. Antegrade perfusion cannulas have been proposed to decrease this risk but the benefit did not reach statistical significance in this case series. Additional study is needed to define the proper role for antegrade perfusion cannula in VA ECMO. Objectives: Loss of independence after surgery has been shown to increase mortality and readmission in geriatric patients. We studied loss of independence in patients undergoing endovascular abdominal aortic aneurysm (AAA) repair (EVAR).
Methods: A total of 16,007 patients undergoing EVAR from 2012 to 2014 in the National Surgical Quality Improvement Program database were analyzed. Comorbidities, including preoperative functional status, were 
